BioMS still positive as dirucotide fails to meet endpoint in Phase II MS trial
This article was originally published in Scrip
Executive Summary
BioMS Medical's Phase II trial of its myelin basic protein stimulant, dirucotide, for the treatment of relapsing-remitting multiple sclerosis (RRMS) - developed with Lilly, has failed to meet its primary endpoint of annualised relapse rate or associated MRI measures. The news sent the company's shares down by 30% to close at Cdn$2.39 on January 30th on the Toronto Stock Exchange.